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Numerous studies have demonstrated that the humoral and cell-mediated 
immune response  can be  modulated by  actively synthesized, as  well  as  by 
passively transferred antibody (1-9). 
The most frequently observed effect of passively administered  antibody is the  sup- 
pressed development of immunological responses by 7S antibodies (1, 2, 10-14). However, 
in certain circumstances both 7S and  19S antibodies have been shown to enhance the 
immune response (2,  3).  While feedback control of the B-cell  (bursa- or bone marrow- 
derived) response by passive antibody has been extensively studied, little information is 
available with regard to its effect  on the development of T-cell  responses (15). Studies 
have shown that delayed-type hypersensitivity (DTH)' appears less readily affected than 
the primary antibody response (1). In fact, Uhr and MSller (1) reported that development 
of DTH was facilitated by antigen-antibody complex. Liew and Parish (5) have shown 
that suppression of antibody formation was accompanied by a  concomitant increase in 
DTH.  These  results,  in  addition  to those  reported  by Mackaness  and  Lagrange  (4), 
suggest that an inverse relationship often exists between DTH and the humoral immune 
response. 
Here we report the effects of passively administered antibody on the in vivo 
development of lymphocyte-mediated cytotoxicity (LMC),  Using an assay that 
has been  demonstrated to  measure  T-cell  cytotoxicity (16,  17),  we  show that 
administration  of minute  quantities  of isoantiserum  (IS)  with  low  doses  of 
allogeneic tumor cells facilitates development of cytotoxic T  cells.  We describe 
this  as  isoantiserum  augmentation  of T-cell  development  to  avoid  confusion 
with immune serum enhancement (8). 
Materials and Methods 
Cell lines.  P-815-X2  mastocytoma cells were obtained from Dr. T. Brunner,  Swiss Institute, 
for Experimental Cancer Research, Lusanne, Switzerland, and maintained  by weekly transfer of 
5 x l0  s ascitic cells in DBA/2J mice (The Jackson Laboratory, Bar Harbor, Maine). EL-4 leukemia 
cells were obtained from Dr. E. A. Boyse, Memorial-Sloan Kettering  Cancer Center, New York, 
and maintained  in C57BL/6 mice. 
* Supported by NCI grants nos. CA-08748, CA-16271, CA-17049, and CA-17404. 
' Abbrevmtions  used in this paper:  BSS, balanced salt solution, BSS-CS, BSS containing 10% 
calf serum; DTH, delayed-type hypersensitivity; H-IS, hyperimmune serum; P-IS, 10-day  primary 
lsoantiserum;  IS, isoantiserum;  LMC, lymphocyte-mediated cytotoxicity; NMS, normal  mouse 
serum; PEC, peritoneal exudate cells; RPMI-CS, RPMI 1640 containing 10% CS. 
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Preparation of  IS.  EL-4 or P-815 cells were collected for immunization by aspirating the ascitic 
fluid  from  tumor-bearing mice.  The  cells  were  washed  with  balanced  salt  solution  (BSS)  by 
centrifugation at 200g for 3 rain. 1-3 ×  107 EL-4 or P-815 cells were injected intraperitoneally (i.p.) 
into female BALB/c or male C57BL/6 mice, respectively. In most cases IS was obtained by bleeding 
mice 10 days after the first injection from the axillary area (I°-IS). Antisera were pooled and heat 
inactivated by incubation for 45 rain at 56°C. The cytotoxic titer of I°-IS was 1/64 as determined by 
the method of Boyse et al. (18), with flesh rabbit serum as a source of complement and P-815 as the 
target cell Hyperimmune serum (H-IS) was prepared by repeated weekly injections of 107 cells for 
a total of four doses. The cytotoxic titer of anti-P-815 H-IS was 1/512, while that for anti-EL-4 was 
1/1,024. 
Preparation of Peritoneal Exudate Cells (PEC) and Spleen Cells.  Immune PEC for the cyto- 
toxic assay were isolated 10-11 days after immunization, as described by Berke et al. (19). Briefly, 
the peritoneal cavity was washed out with 5 ml BSS containing 10% calf serum (BSS-CS) and 5 U 
heparin/ml. PEC were allowed to adsorb to the nylon wool (20) for 45 min at 37°C in a humidified 
CO2 incubator.  Unattached cells were eluted by permitting 30 ml of media to flow through the 
column.  The eluted PEC  were collected by centrifugation at 450 g  for 5 min and suspended in 
RPMI-1640 containing 10% calf serum (RPMI-CS). 
To prepare immune spleen cells,  spleens were removed from immunized animals and teased 
apart in BSS.  Cell debris was allowed to settle for 10 rain at 0°C.  Spleen cells were decanted, 
washed twice with BSS, and suspended in RPMI-CS. 
Cytotoxic Assay.  P-815  target  cells  were  isolated  from  the  ascitic  fluid  of tumor-bearing 
mice and labeled with  51Cr as  previously  described  (21).  To  measure  in vitro LMC,  0.5  ml of 
suspensions containing 1  x  105 P-815 cells/ml and 5-50  ×  105 immune lymphoid cells/ml were 
incubated in 35-mm plastic Petri dishes (Falcon Plastics, Div. of BioQuest, Los Angeles, Calif.) on 
a rocking platform at 37°C in a humidified incubator (22). At several time points, 51Cr released into 
the culture media was monitored, and the percent specific 5~Cr release was calculated as previ- 
ously described: % specific 5~Cr release  =  [(experimental release  -  spontaneous release)/(total 
release  -  spontaneous release)]  x  100 (23). 
Sephadex G-200 Fractionation oflsoantiserum.  A 2- to 3-ml sample of pooled anti-P-815 serum 
was applied to a  Sephadex G-200 column (2.5 ×  100 cm) and eluted by upward flow at a rate of 20 
ml/h with  0.3  M  NaCI  in  0.1  M  Tris-HC1,  pH  7.4.  The  fractions eluting at  the  void volume 
containing IgM (Peak I) and the fractions containing IgG (Peak II) were pooled separately and 
concentrated at 4°C by pressure dialysis to the original serum volumes and kept frozen at -20°C 
until used. 
Results 
Effect of IS on the Induction of Lymphocyte-Mediated  Cytotoxic LMC Activ- 
ity.  The effect of I°-IS on the induction of lymphocyte cytotoxic activity was 
studied  by  immunizing  C57BL/6  (H-2b)  mice  with  allogeneic  P-815  (H-2d) 
tumor cells coated with I°-IS. I°-IS was serially diluted in normal C57BL/6 serum 
to assure that each animal received an equivalent dose of serum protein. The 
diluted serum was mixed with P-815 cells, incubated at 37°C for 30 min, and an 
aliquot of 5 ×  105 cells was injected i.p. per mouse. 10 days later LMC activity of 
PEC  or  splenic  lymphoid cells  was  measured  using  ~Cr-labeled  P-815  as  a 
target. 
As shown in Fig.  l a  PEC from mice immunized with mixtures of I°-IS and 
tumor cells consistently showed significantly greater LMC activity than PEC 
from mice injected with P-815 alone or P-815 in BSS or P-815 in normal mouse 
serum  (NMS).  The observed I°-IS effect on development of LMC  activity oc- 
curred  within  a  narrow  range  of I°-IS  dilution  and  decreased  upon  further 
dilution of I°-IS.  The I°-IS augmentation of cytotoxicity was  not restricted to 
PEC. Splenic lymphoid cells isolated from the same animals exhibited the same 
results (Fig.  1 b). 1286  LYMPHOCYTE-MEDIATED  CYTOTOXICITY 




,-r  60 
£3 
~  40 
l.O 
) 
1234567  1  234567 
Dose of IS 
FIG.  1.  IS augmentation of LMC activity. The primary IS was serially diluted in 1% NMS 
from the tube that contained 20 ~tl IS in 0.5 ml 1% syngeneic NMS-BSS.  5  ×  106 mastocy- 
toma cells were suspended in 0.5 ml of the 1% NMS-BSS containing various concentrations 
of I°-IS, incubated for 30 rain at 37°C,  and then aliquots of mixtures containing 5 ×  10  ~ cells 
were injected i.p. into C57BL/6 mice. Dose of IS: (1) BSS, (2) 1% NMS, (3) 2 ~1, (4) 1.0 ~1, (5) 
0.5 ~1, (6) 0.25 ~l, and (7) 0.125 ~1. (a) PEC were isolated and assayed for LMC activity at a 
lymphocyte to target cell ratio of 10:1 at the assay period of 2 h; (b) splenic lymphoid cells 
were assayed at a lymphocyte to target cell ratio of 50:1. The data are the mean of duplicate 
samples removed at 2 h  and are representative of 10 experiments. 
The  IS-augmented  induction  of cytotoxicity was observed at doses of P-815 
cells below that required for optimal stimulation of LMC activity. Therefore, it 
was possible that "augmentation"  was simply explained on the basis of serum- 
stimulated growth of the P-815 in mice in the peritoneal cavity, since several 
other investigators have reported results to this effect (24). 
If the P-IS augmentation was merely serum-mediated increased proliferation 
of P-815, resulting in a greater antigenic dose in the IS-containing mixtures, the 
effect would be abrogated by irradiation.  We found irradiated  P-815 cells to be 
significantly less immunogenic than normal P-815. We, therefore, determined a 
minimal  immunizing  dose of 1,500 R irradiated P-815 to be in the range  of 106 
cells per mouse.  Antibody-P-815 mixtures  were incubated at 37°C for 30 min, 
then irradiated. As shown in Table I, irradiation significantly affects the immu- 
nogenicity of P-815 in that the cytotoxic activity of the PEC is low. The mice 
receiving 5 ~1 NMS show less cytotoxicity at all time points than mice receiving 
5 ~l IS,  excluding the above described explanation for the IS augmentation  of 
LMC. 
Specificity  of Isoantiserum-Augmented  Induction  of LMC Activity.  Since 
several reports have described serum factors which nonspecifically induce LMC 
(25),  the  specificity  of the  I°-IS-augmented  induction  of LMC  activity  was 
investigated.  The IS augmentation  of LMC development was not unique to P- 
815.  Another  well-characterized  allogeneic tumor system also showed similar 
results when IS-coated EL-4 tumor cells were used as the immunogen (Table II, R.  FAANES,  M.  WALKER,  AND  Y.  S.  CHOI  1287 
TABLE  I 
IS Augmentation of  LMC Activity against Irradiated P-815 Cells 
Incubation time  NMS  IS* 
rain  %  Specific  ~ICr releases 
180  6.6  ±  0.5  13.5  -+  0.1 
270  13.0  ±  1.7  31.7  ±  1.7 
*  Irradiated  P-815  cells were  incubated  with  NMS  or IS at  37°C for 30 
min.  The  cell  suspensions  were  subjected  to  1,500  R  X  irradiation 
before  injecting  10  e  cells  per  mouse  with  5  /~1  of  IS.  This  dose  of 
irradiation did not allow growth  of P-815  in  DBA/2J. 
Data  represent  the mean of duplicate  samples  removed  from the assay 
mixture  at the time  specified. 
TABLE II 
Specific IS Induction of Cytotoxic T-Cell Activity 
Immunizing  Specificity  Respender  Target 
cell  of IS  cell  NMS 
~l I°-IS/Mouse * 
20  1.0  0.5  0.25 
% Specific ~Cr release$ 
EL-4  Anti-EL-4  BALB/c (H-2 e)  EL-4  22.4 ±  2.8  9.5 ±  2.3  88.5 ± 5.1  - 
P-815§  Anti-P-815  C57BL/6 (1t-2 °)  P-815  17.2 -+ 2.5  19.1 -* 1.1  21.9 ±  1 1  16 2 ± 0.4  - 
-[[  Anti-P-815  C57BL/6  P-815  6.7 ± 0.4  7.0 ±  0 2  6.8 ± 0.8  5.4 ± 0.1  - 
P-815 (H-2 d)  Anti-P-815  C57BL/6  P-815  8.6 ± 0.4  10.4 -+ 0.1  23.1 ±  1 1  44.0 ±  2.0  6.1  -+ 0.7 
P-815  Anh-P-815  C57BL/6  EL-4  1.9 ±  0.1  2.0 ±  0.1  0 7 ± 0 8  1.5 ±  0.4  - 
EL-4 (H-2 °)  Anti-P-815  BALB/c  EL-4  0.9 ± 0.3  4.5 -+ 0.6  9.1  ± 2 1  3.6 ±  0.4  16.8 ± 0.2 
* Dilutions of IS made in 1% NMS as described in Fig. 1. 
Data are from a  150 min time pmnt at a lymphocyte to target cell raho of 10:1, and represents the mean of dupheate samples from the 
same assay mixture. 
§ P-815 cells incubated with IS above were washed twice in BSS, diluted to 5 x  10  e cells/ml, and 5 × 10  s P-815 cells were injected per mouse. 
II IS incubated with 5 x  106 P-815 cells in 0.6 ml at 0°C for 30 min. The cells were pelleted, washed with BSS, and then incubated at 37°C for 30 
ram.  The cells were pelleted. The supernates were diluted 1/5 and 0.5 ml was injected per mouse. 
line 1). Anti-EL-4 antiserum increased the cytotoxic activity of PEC against EL- 
4 cells. 
To  further  characterize  the  augmenting  activity,  we  investigated  whether 
antiserum-coated tumor cells functioned as well as antiserum tumor cell mix- 
tures in augmenting  induction  of LMC  activity.  When P-815  cells were sepa- 
rated from IS after 37°C  incubation,  PEC  from mice receiving the cell pellets 
(line 2) and those from mice receiving culture supernates (line 3) failed to induce 
detectable  levels of LMC  10 days after immunization.  Thus,  IS augmentation 
was reproducibly observed only when whole mixtures of cells and IS are injected 
together. 
PEC from mice immunized with I°-IS-coated P-815 cells showed cytotoxicity 
specific for the  alloantigens  of P-815  (H-2d) (line 4),  because PEC  from mice 
showing IS-augmented  cytotoxic activity showed no detectable cytotoxicity to- 
ward EL-4 (H-2b) (line 5). Anti-P-815 serum administered with EL-4 cells failed 
to  augment  development  of LMC  against  P-815  (line  6).  Furthermore,  when 
anti-P-815 IS was adsorbed with P-815 cells (10 s cells/ml IS) to remove in vitro 
LMC-blocking activity  (23),  augmenting  activity  of IS was also removed from 
the  serum  (Table  III).  Anti-P-815  IS absorbed  with EL-4  leukemia  cells  as  a 1288  LYMPHOCYTE-MEDIATED  CYTOTOXICITY 
TABLE HI 
Removal of  IS-Augmenting Activity after Absorbing Serum with P-815 
Absorbing cell  Exp.  no.  NMS 
~1 I°-IS  serum  per mouse* 
2.0  1.0  0.5  0.25 
% Specific ~'Cr release 
1  9.1  +- 0,4  9.0  ±  0,0  13.2  ±  0.2  15.9  ±  0.0  29.6  ±  2.0 
2  24.6  ±  0.6  19.3  ±  0.3  57.0  ±  0.8  38.3  ±  0.4  80.5  ±  1.4 
EL-4$  1  -  58.7  ±  3.0  37.2  ±  0.1  29.1  ±  1.4  21.6  _+  0.6 
2  -  46.4  ±  1.8  64.8  ±  1.3  46.7  ±  2.1  73.5  ±  2.8 
P-8155  1  -  19.0  ±  0.2  18.7  ±  0.1  7.3  ±  0.1  16.2  +-  0.3 
2  -  22.7  _  0.1  16.6  +-  0.3  10.5  ±  0.2  2.1  _  0.1 
* IS diluted in 1% NMS, as in Fig. 1. 
1.0 ml of serum was adsorbed three times with 1 × 108 EL-4/ml serum. The serum was divided 
into 0.5-ml aliquots. 0.5 ml was further adsorbed three times with 1 × 108 P-815/ml of serum. 
Data represent the mean of duplicate samples removed from assay mixture at 180 min at a 
lymphocyte  to target cell ratio of 10-15:1. 
control retained the capacity to increase cytotoxic T-cell activity. We found in 
these studies that the nonspecific absorption with EL-4 actually increased the 
augmenting activity of the P-IS. Possibly, the absorption removes autoantibod- 
ies that counteract the augmenting activity of the serum.  These results show 
that the serum factor responsible for augmenting cytotoxic T-cell development 
possessed immunological specificity. It was, therefore, important to show that Ig 
was the serum component causing the effect. 
G-200 Sephadex  Fractionation  of P-IS ~and H-IS.  Primary and  hyperim- 
mune serum were fractionated on G-200  Sephadex.  The pooled peak fraction 
(Peak I) eluting at the void volume containbd IgM, as identified by immunoelec- 
trophoresis with goat antimouse-Ig, and the second peak which was retained in 
the column (Peak II) contained IgG. 
As shown in Table IV, Peak I from P-IS showed in vivo augmentation of LMC 
activity;  PEC  from  mice  receiving  P-815  coated  with  Peak  I  of P-IS  were 
significantly more  cytotoxic (41%  at  a  0.5  /~l/mouse  dilution  vs.  7%  in  the 
control) than  PEC from mice receiving Peak I  of H-IS (28%  at a  2  ~l/mouse 
dilution). 
The pooled G-200  fractions from P-IS ~d  H-IS were also assayed for their 
ability to block in vitro LMC  (Table V).  Primary serum has little detectable 
blocking effect on LMC against P-815 (line 1). The hyperimmune serum, how- 
ever, shows significant blocking activity in peak II  (line 3)  (19% kill vs.  59% 
found with NMS Peak II) as previously described (23, 26). 
Since IgM production precedes that of IgG, we investigated whether or not 
augmenting  activity  coincided  with  the  development  of  blocking  activity. 
C57BL/6 mice were immunized with  107  DBA mastocytoma cells and bled  10 
days later, before a booster immunization. The weekly bleeding and immuniza- 
tion were repeated four times. The serum from each bleeding was monitored for 
its capacity to augment the in vivo development of cytotoxic T cells by injecting 
it with P-815 cells (Table VI) and for its capacity to block in vitro LMC (Fig. 2). R.  FAANES,  M.  WALKER,  AND  Y.  S.  CHOI  1289 
TABLE  IV 
Augmenting activity of G-200 Fractionated Primary and Hyperimmune Serum 
NMS 
#tl of fraction/mouse* 
2.0  1.0  0.5  0.25 
%  Specific 51Cr releases 
I°-IS PK I  6.9 ±  0.3  4.9 -  1.1  20.3 _+ 0.4  41.1  -+ 1.6  1.7 ±  0.5 
I°-IS PK II  5.2 -  1.2  14.9 -+ 0.8  14.6 _+ 1.2  21.9 -+ 1.1  14.8 ±  0.1 
H-IS PK I  6.1  ±  0.9  28.8 ±  2.6  -  7.1  -  1.3  7.0 -+ 0.1 
H-IS PK II  6.1  ±  0.9  6.5 ±  1.0  -  3.1  ±  0.2  5.6 ±  0.0 
* IS diluted in 1% NMS, as in Fig.  1. 
* Data represent one of three experiments, the mean of duplicate samples removed from the assay 
mixture at an assay time of 240 min at a  lymphocyte:target cell ratio of 5:1. 
TABLE V 
Blocking of  LMC by G-200 Fractionated l O-Day Anti-P-815  and 
H-IS 
Serum fraction  NMS*  I°-IS  H-IS 
% 51Cr release* 
Whole mouse serum  53.3 -+ 1.5  60.2 -+ 0.6  12.2  ±  0.8 
PK I  58.1  -+ 0.3  59.2 ±  1.8  58.0 ±  0.1 
PK II  59.4 _+ 1.3  50.2 ±  0.4  18.6 ±  0.6 
* Antiserum added to final concentration of 5% in the assay mixture. 
$ Results represent the mean of duplicate samples removed at 150 min 
at a  lymphocyte to target cell ratio of 10:1. 
TABLE  VI 
Chronological Development of Immune Serum Augmenting Activity 
No.  of  Days of  NMS 
immunizations*  bleedingS 
~1 Serum per mouse 
1  5  10 
% Specific 5'Cr release§ 
1  10  17.8 ±  1.8  23.0 ±  0.8  29.3  ±  4.2  44.7 ±  3.7 
2  17  1.9 ±  0.2  5.2 _  0.1  65.3  +  2.3  3.8 ±  0.6 
3  24  17.7 ±  0.1  39.6 -_+ 0.7  37.1  ±  1.2  - 
4  31  0.4 -+ 0  28.7 _+ 0.5  2.3 -+ 0.4  - 
* Mice received 1  ×  107 cells per booster. 
$ Days after first immunization (Fig. 2). 
§ Data represent the mean of duplicate samples removed at 150 rain at lymphocyte to target cell 
ratios of 13:1. 
A  significant  level  of augmenting  activity  was  present  in the  serum  after  the 
first  immunization  (Table  VI,  line  1).  As  the  number  of  immunizations  in- 
creased,  it was  more  difficult  to consistently  demonstrate  the  serum-augment- 
ing activity  as evidenced  by the  data  in Table  VI (lines 2-4).  The  inconsistencies 
in augmentation  of LMC  activity  appear  when  serum-blocking  activity  became 
more  pronounced  (Fig.  2  and  Table  VI,  lines  3  and  4). 1290  LYMPHOCYTE-MEDIATED  CYTOTOXICITY 
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FIG. 2.  Chronological appearance of  in vitro  LMC-blocking activity.  LMC-blocking activ- 
ity  at  the  assay period  of  2 h was monitored on  the day of  bleeding  before a booster injectlon 
of  107  P-815 cells,  as indicated by arrows, (@);  control experiments with hyperimmune sera 
were performed each time, (O).  The data represent the mean of  three experiments. 
Discussion 
Using an assay system which measures "pure" T-cell immune responses (16, 
17),  we  show  that  passive  administration  of IS  with  aUogeneic  tumor  cells 
modulates the induction of LMC activity. We present evidence that the factor in 
IS is likely to be specific antibody induced by immunization:  (a) both in vivo 
augmenting and in vitro blocking activities are present in IS; (b) both activities 
are  removed  by absorption  with  specific  cells;  and  (c)  demonstration  of the 
augmentation  effect requires  injection  of tumor  cells  plus  IS  together.  The 
augmentation effects were best manifested when mice were immunized with low 
doses of tumor cells. 
The  IS-augmented  induction  of LMC  activity  is  similar  to  the  enhanced 
development of PFC when mice received antiserum and SRBC together (2,  3). 
These studies demonstrated that 19S antibodies may stimulate PFC formation, 
whereas 7S antibodies usually suppressed. Henry and Jerne (2) also emphasized 
that  stimulation  of PFC  by immune  sera  required  low doses of antigen.  In 
agreement  with these observations,  our results  showed that the IS effects on 
induction  of LMC activity was best manifested when the dose of immunizing 
tumor cells was low.  Our  experimental  results  suggest that  the  augmenting 
factor in immune serum was 19S antibody, because the activity appears within 
10 days after a  primary injection and migrates  with the  19S fraction in G-200 
chromatography.  Development of in vivo augmenting activity, after immuniza- 
tion, occurs before significant levels of in vitro LMC-blocking activity occurs in 
the serum (Table V  and Fig. 2). 
It  is known that  administration  of serum from tumor-bearing  animals  can 
result in enhanced tumor growth (8). In these cases, 7S antibodies appear to be 
responsible for the enhancement  (10-12).  On the other hand,  evidence is also 
accumulating  that  indicates  that  passively  administered  immune  sera  may 
suppress rather than enhance tumor growth (27-29). The latter studies failed to R.  FAANES,  M.  WALKER,  AND  Y.  S.  CHOI  1291 
show whether or not 7S antibodies were involved in suppression of the tumor 
growth. 
The presence of an antigen-antibody complex in the sera of tumor-bearing 
mice has been known (30). A paradox has evolved, however, with regard to the 
role of immune complexes in regulating expression of immunological functions. 
Several investigators have suggested that immune complexes suppress both the 
humoral and cellular immune response  (31, 32), while others have reported 
stimulation  (33). These contrasting results are  reconcilable if one considers 
manifestations of the antigen vs. antibody composition of the immune complex 
(34, 35) or the physiological difference between 7S complex and 19S complex. It 
appears possible  that the development of either a humoral or cellular immune 
response is delicately balanced between the level of 7S vs. 19S antibody produc- 
tion and the consequent formation of antigen-antibody complex. 
The exact role of passively administered antibody in augmenting T-cell re- 
sponses is presently not understood. Our experimental evidence is unique in 
revealing that antigen-antibody complex has a profound effect on development 
of LMC activity. It does appear that formation of the antigen-antibody complex 
is intimately involved in influencing expression of specific T-cell activity. We 
have found, as have others, that antibody and antigen must combine in optimal 
proportions to achieve the observed effects on LMC activities (Fig.  1), although 
the influence of IgG-immune complex vs.  IgM-immune complex influence on 
development of immune responses has yet to be delineated. Our data indicates 
that !gM-immune complex augments development of LMC while the IgG-im- 
mune complex works in an opposing fashion. 
Playfair (15) has postulated that antigen binding, augmentation of antibody 
production, and suppression of antibody production can be mediated by pas- 
sively acquired Ig on the surface of T cells,  suggesting that Ig can attach to T 
cells with or without being complexed with antigen. In fact, Hudson and Sprent 
(36) have recently shown that  IgM antibody is specifically adsorbed to  H-2- 
activated mouse T lymphocytes. 
The described observations tempt one toward a  simple hypothesis. Inbred 
"normal" mice are now known to contain significant amounts of natural anti- 
body (37); therefore, they may contain low levels of alloactivated T cells.  The 
passive administration of IgM with antigen negates the animal's requirement to 
produce an endogenous supply.  Macrophages recognize the IgM-antigen com- 
plex,  and through their digestion produce processed IgM-antigen complexes, 
which adsorb to the omnipresent, activated T cells initiating elonal expansion of 
the specific cytotoxic T cell. This proposal is currently being investigated in this 
laboratory. 
Summary 
Passive administration of anti-P-815  isoantiserum (IS) with P-815 mastocy- 
toma was shown to augment the development of T-lymphocyte-mediated  cyto- 
toxicity (LMC). The LMC activity augmented by IS was specific to immunizing 
tumor cells, but required the simultaneous administration of P-815 tumor cells 
and anti-P-815 serum, suggesting that the antigen-antibody complex is involved 
in the development of specific cytotoxic T cells. 1292  LYMPHOCYTE-MEDIATED  CYTOTOXICITY 
The serum component responsible for augmented development of LMC activ- 
ity appeared to be IgM in that the augmenting activity fractionated in the void 
volume of a  G-200 Sephadex column and appears very early after immunization. 
Our experimental results suggest the development of specific T-cell cytotoxicity 
can be directly regulated by specific IgM antibodies. 
The authors wish to extend their appreciation to Dr. G. Dennert for his helpful discussions  and 
critical review of this manuscript, and to Charles Barinaga and Steve Calvano for their technical 
assistance. 
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